Matrix metalloproteinase (MMP) inhibitors and methods of use thereof
Grant
US12583844B2
Kind: B2
Mar 24, 2026
Assignee
Foresee Pharmaceuticals USA, Inc.
Inventors
Wenjin Yang, Kai-Wei Chang
Abstract
Hydantoin based compounds useful as inhibitors of matrix metalloproteinases (MMPs), particularly macrophage elastase (MMP-12) are described. Also described are related compositions and methods of using the compounds to inhibit MMP-12 and treat diseases mediated by MMP-12, such as asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, nonalcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis.
CPC Classifications
C07D 405/14
C07D 409/14
C07D 401/14
C07D 403/14
Filing Date
2020-11-13
Application No.
17755983
Claims
16